Home › NDC Lookup › RxCUI directory › RxCUI 861210

Brimonidine tartrate 1.5 MG/ML Ophthalmic Solution [Alphagan] — RxCUI 861210

Name: Brimonidine tartrate 1.5 MG/ML Ophthalmic Solution [Alphagan] (RxCUI 861210)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 861210 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 7 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI861210

Official nameBrimonidine tartrate 1.5 MG/ML Ophthalmic Solution [Alphagan]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asAlphagan P 0.15 % Ophthalmic Drops; Alphagan P 0.15 % Ophthalmic Solution; Alphagan 1.5 MG/ML Ophthalmic Solution

FDA products mapped2

Package NDCs mapped7

Reported Medicaid activity (SDUD)42,527 prescriptions · 33 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Brimonidine Ophthalmic: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Brimonidine eye drops are used to lower the pressure inside your eye — what doctors call intraocular pressure. High eye pressure is a key risk factor for glaucoma-related vision da...
What exactly is brimonidine eye drops used for?
The usual routine is one drop in the affected eye or eyes, three times a day — roughly 8 hours apart, so think morning, afternoon, and evening. If you use other eye drops too, wait...
The most common ones are eye redness, itching, a burning or stinging sensation, and dry mouth. Some people also notice drowsiness or blurred vision. These are usually manageable, b...

📖 Read our full Brimonidine Ophthalmic guide →

🕸️ Concept Web — How Brimonidine tartrate 1.5 MG/ML Ophthalmic Soluti... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Brimonidine tartrate 1.5 MG/ML Ophthalmic Solution [Alphagan] RxCUI 861210 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 2

The active substance itself — no strength, form, or brand attached yet.
- Brimonidine 134615 IN
- Brimonidine tartrate 39171 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Alphagan 153358 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Brimonidine Ophthalmic Solution 378723 SCDF
- Brimonidine tartrate Ophthalmic Solution 2645974 SCDFP
- Brimonidine Ophthalmic Product 1163094 SCDG
- Brimonidine tartrate Ophthalmic Product 2660235 SCDGP
- Brimonidine Ophthalmic Solution [Alphagan] 363786 SBDF
- Brimonidine tartrate Ophthalmic Solution [Alphagan] 2656200 SBDFP
- Alphagan Ophthalmic Product 1169203 SBDG
- Ophthalmic Solution 7670 DF
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Brimonidine tartrate 1.5 MG/ML Ophthalmic Solution 861208 SCD
- Brimonidine tartrate 1.5 MG/ML 861207 SCDC
- Brimonidine tartrate 1.5 MG/ML [Alphagan] 861209 SBDC

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brimonidine tartrate 1.5 MG/ML Ophthalmic Solution SCD · 861208
Brimonidine tartrate 1.5 MG/ML SCDC · 861207
Brimonidine Ophthalmic Solution SCDF · 378723
Brimonidine tartrate Ophthalmic Solution SCDFP · 2645974
Brimonidine Ophthalmic Product SCDG · 1163094
Brimonidine tartrate Ophthalmic Product SCDGP · 2660235

Brand-Name Concepts

Brimonidine tartrate 1.5 MG/ML [Alphagan] SBDC · 861209
Brimonidine Ophthalmic Solution [Alphagan] SBDF · 363786
Brimonidine tartrate Ophthalmic Solution [Alphagan] SBDFP · 2656200
Alphagan Ophthalmic Product SBDG · 1169203
Alphagan BN · 153358

📦 FDA Products & Package NDCs

2 products · 7 package NDCs

7 package NDCs map to RxCUI 861210 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00023-9177-05	1 BOTTLE, DROPPER in 1 CARTON (0023-9177-05) / 5 mL in 1 BO...	ALPHAGAN P	Allergan, Inc.	2001-07-10
00023-9177-10	1 BOTTLE, DROPPER in 1 CARTON (0023-9177-10) / 10 mL in 1 B...	ALPHAGAN P	Allergan, Inc.	2001-07-10
00023-9177-15	1 BOTTLE, DROPPER in 1 CARTON (0023-9177-15) / 15 mL in 1 B...	ALPHAGAN P	Allergan, Inc.	2001-07-10
00023-9321-03	1 BOTTLE, DROPPER in 1 CARTON (0023-9321-03) / 3 mL in 1 BO...	ALPHAGAN P	Allergan, Inc.	2006-01-25
00023-9321-05	1 BOTTLE, DROPPER in 1 CARTON (0023-9321-05) / 5 mL in 1 BO...	ALPHAGAN P	Allergan, Inc.	2006-01-25
00023-9321-10	1 BOTTLE, DROPPER in 1 CARTON (0023-9321-10) / 10 mL in 1 B...	ALPHAGAN P	Allergan, Inc.	2006-01-25
00023-9321-15	1 BOTTLE, DROPPER in 1 CARTON (0023-9321-15) / 15 mL in 1 B...	ALPHAGAN P	Allergan, Inc.	2006-01-25

Observed labelers: Allergan, Inc. (7) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.